Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
respiratory syncytial virus vaccine (bivalent, recombinant)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
RSVpreF (Abrysvo) is a nonadjuvanted, bivalent recombinant protein subunit vaccine developed by Pfizer for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). The vaccine consists of equal amounts of stabilized prefusion F (preF) antigens from the two major RSV subgroups, RSV-A and RSV-B. It is approved for active immunization of individuals 60 years of age and older, adults aged 18 to 59 years who are at increased risk for RSV-associated LRTD, and pregnant individuals at 32 through 36 weeks of gestation to provide passive protection to infants from birth through 6 months of age.
- Brand names
- Abrysvo
- Other names
- RSVpreFRSVpreF protein subunit vaccinerespiratory syncytial virus vaccinerespiratory syncytial virus vaccine (bivalent, recombinant)
02
Targets
RSV-A PreF (Respiratory syncytial virus subtype A prefusion fusion glycoprotein)RSV preF (Respiratory syncytial virus prefusion F glycoprotein)
Beyond the preview
Go deeper on respiratory syncytial virus vaccine (bivalent, recombinant).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on respiratory syncytial virus vaccine (bivalent, recombinant).